R.O. Mirimanoff

35.6k total citations · 4 hit papers
71 papers, 26.4k citations indexed

About

R.O. Mirimanoff is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Surgery. According to data from OpenAlex, R.O. Mirimanoff has authored 71 papers receiving a total of 26.4k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Pulmonary and Respiratory Medicine, 25 papers in Genetics and 18 papers in Surgery. Recurrent topics in R.O. Mirimanoff's work include Glioma Diagnosis and Treatment (24 papers), Brain Metastases and Treatment (17 papers) and Advanced Radiotherapy Techniques (10 papers). R.O. Mirimanoff is often cited by papers focused on Glioma Diagnosis and Treatment (24 papers), Brain Metastases and Treatment (17 papers) and Advanced Radiotherapy Techniques (10 papers). R.O. Mirimanoff collaborates with scholars based in Switzerland, Netherlands and Belgium. R.O. Mirimanoff's co-authors include Roger Stupp, Michael Weller, J. Gregory Cairncross, Warren Mason, Thierry Gorlia, Robert C. Janzer, Martin J. van den Bent, Alba A. Brandes, Denis Lacombe and Elizabeth A. Eisenhauer and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Neurology.

In The Last Decade

R.O. Mirimanoff

67 papers receiving 26.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

2005 16.0k citations Roger Stupp, Warren Mason et al. New England Journal of Medicine profile →
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

2005 5.2k citations Monika E. Hegi, Annie‐Claire Diserens et al. New England Journal of Medicine profile →
Meningioma: analysis of recurrence and progression following neurosurgical resection

1985 837 citations R.O. Mirimanoff et al. profile →
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide

2002 630 citations Roger Stupp, Pierre-Yves Dietrich et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R.O. Mirimanoff Switzerland	30	16.4k	8.3k	6.9k	5.7k	4.5k	71	26.4k
Michael D. Prados United States	90	18.8k 1.1×	7.9k 1.0×	7.4k 1.1×	4.6k 0.8×	4.9k 1.1×	418	27.6k
Robert C. Janzer Switzerland	32	15.7k 1.0×	9.1k 1.1×	5.7k 0.8×	5.6k 1.0×	4.3k 1.0×	67	25.5k
Christine Marosi Austria	46	14.7k 0.9×	7.2k 0.9×	5.6k 0.8×	4.8k 0.8×	4.5k 1.0×	196	24.4k
Thierry Gorlia Belgium	46	20.6k 1.3×	10.3k 1.2×	8.1k 1.2×	7.3k 1.3×	5.4k 1.2×	158	31.2k
Raymond Sawaya United States	84	11.6k 0.7×	8.4k 1.0×	7.2k 1.1×	5.0k 0.9×	7.9k 1.8×	351	28.2k
Mark R. Gilbert United States	77	15.1k 0.9×	6.6k 0.8×	6.8k 1.0×	4.5k 0.8×	5.9k 1.3×	491	24.8k
Anouk Allgeier Netherlands	22	13.1k 0.8×	6.6k 0.8×	4.9k 0.7×	4.1k 0.7×	3.2k 0.7×	33	19.8k
Martin Taphoorn Netherlands	39	15.2k 0.9×	6.5k 0.8×	5.8k 0.9×	4.6k 0.8×	4.0k 0.9×	156	22.4k
Allan H. Friedman United States	75	12.2k 0.7×	7.2k 0.9×	4.8k 0.7×	4.6k 0.8×	5.6k 1.3×	345	25.7k
J. Gregory Cairncross Canada	60	24.9k 1.5×	12.5k 1.5×	9.4k 1.4×	8.4k 1.5×	5.9k 1.3×	169	36.1k

Countries citing papers authored by R.O. Mirimanoff

Since Specialization

Citations

This map shows the geographic impact of R.O. Mirimanoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R.O. Mirimanoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R.O. Mirimanoff more than expected).

Fields of papers citing papers by R.O. Mirimanoff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R.O. Mirimanoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R.O. Mirimanoff. The network helps show where R.O. Mirimanoff may publish in the future.

Co-authorship network of co-authors of R.O. Mirimanoff

This figure shows the co-authorship network connecting the top 25 collaborators of R.O. Mirimanoff. A scholar is included among the top collaborators of R.O. Mirimanoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R.O. Mirimanoff. R.O. Mirimanoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boujelbene, N., Abdelmajid Khabir, Wendy Jeanneret Sozzi, R.O. Mirimanoff, & K. Khanfir. (2011). Clinical review – Breast adenoid cystic carcinoma. The Breast. 21(2). 124–127. 56 indexed citations

Klein, Martin, L. Claassens, Neil K. Aaronson, et al.. (2010). An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer. 46(6). 1033–1040. 272 indexed citations

Collette, Sandra, Laurence Collette, Tom Budiharto, et al.. (2008). Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer – A study based on the EORTC trial 22881–10882 ‘boost versus no boost’. European Journal of Cancer. 44(17). 2587–2599. 157 indexed citations

Mak, Ki M., Robert C. Miller, Normand Laperrière, et al.. (2007). Outcomes and Prognostic Factors in Primary Intraocular Lymphoma: A Multicenter Rare Cancer Network Study. International Journal of Radiation Oncology*Biology*Physics. 69(3). S534–S535. 1 indexed citations

Mauer, Murielle, Roger Stupp, Martin Taphoorn, et al.. (2007). The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study. British Journal of Cancer. 97(3). 302–307. 91 indexed citations

Gorlia, Thierry, Martin J. van den Bent, Monika E. Hegi, et al.. (2007). Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. The Lancet Oncology. 9(1). 29–38. 412 indexed citations

Özsahin, Mahmut, Patrice Jichlinski, Damien C. Weber, et al.. (2006). Treatment of penile carcinoma: To cut or not to cut?. International Journal of Radiation Oncology*Biology*Physics. 66(3). 674–679. 35 indexed citations

Özsahin, Mahmut, Michael Betz, Oscar Matzinger, et al.. (2006). Feasibility and Efficacy of Subcutaneous Amifostine Therapy in Patients With Head and Neck Cancer Treated With Curative Accelerated Concomitant-Boost Radiation Therapy. Archives of Otolaryngology - Head and Neck Surgery. 132(2). 141–141. 20 indexed citations

Hegi, Monika E., Annie‐Claire Diserens, Thierry Gorlia, et al.. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. New England Journal of Medicine. 352(10). 997–1003. 5232 indexed citations breakdown →

10.

Stupp, Roger, Warren Mason, Martin J. van den Bent, et al.. (2005). Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine. 352(10). 987–996. 15995 indexed citations breakdown →

11.

Voelter, Verena, et al.. (2005). L'annonce : d'une mauvaise nouvelle en oncologie : cancer. Revue Médicale Suisse. 1(20). 1350–1353. 6 indexed citations

12.

Senan, Suresh, Dirk De Ruysscher, P. Giraud, R.O. Mirimanoff, & Volker Budach. (2004). Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiotherapy and Oncology. 71(2). 139–146. 166 indexed citations

13.

Azria, D., Sophie Gourgou, Wendy Jeanneret Sozzi, et al.. (2004). Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. British Journal of Cancer. 91(7). 1251–1260. 71 indexed citations

14.

Eberhardt, Wilfried, Kathy S. Albain, Harvey I. Pass, et al.. (2003). Induction treatment before surgery for non-small cell lung cancer. Lung Cancer. 42(2). 9–14. 44 indexed citations

15.

Mirimanoff, R.O. & Roger Stupp. (2003). Radiotherapy in low-grade gliomas: cons. Seminars in Oncology. 30(6 Suppl 19). 34–38. 5 indexed citations

16.

Stupp, Roger, Robert C. Janzer, Monika E. Hegi, Jean‐Guy Villemure, & R.O. Mirimanoff. (2003). Prognostic factors for low-grade gliomas. Seminars in Oncology. 30(6 Suppl 19). 23–28. 44 indexed citations

17.

Stupp, Roger, Pierre-Yves Dietrich, Alessia Pica, et al.. (2002). Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide. Journal of Clinical Oncology. 20(5). 1375–1382. 630 indexed citations breakdown →

18.

Zografos, Léonidas, et al.. (1998). Radiotherapy of choroidal metastases. Radiotherapy and Oncology. 46(3). 263–268. 66 indexed citations

19.

Coucke, Philippe, et al.. (1997). Cell Line Specific Radiosensitizing Effect of Zalcitabine (2',3'-dideoxycytidine). Acta Oncologica. 36(2). 199–205. 1 indexed citations

20.

Mirimanoff, R.O.. (1994). Concurrent chemotherapy (CT) and radiotherapy (RT) in locally advanced non-small cell lung cancer (NSCLC): a review. Lung Cancer. 11. S79–S99. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact